The 3020insC allele of NOD2 predisposes to cancers of multiple organs

Hereditary Cancer in Clinical Practice

Volumn 3, Issue 2, 2005, Pages 59-63

  Lubiński, Jan ^a   Huzarski, Tomasz ^a   Kurzawski, Grzegorz ^a   Suchy, Janina ^a   Masojć, Bartłomiej ^a   Mierzejewski, Marek ^a   Lener, Marcin ^b   Domagała, Wenancjusz ^a   Chosia, Maria ^a   Teodorczyk, Urszula ^a   Mȩdrek, Krzysztof ^a   Dȩbniak, Tadeusz ^a   Złowocka, Elzbieta ^a   Gronwald, Jacek ^a   Byrski, Tomasz ^a   Grabowska, Ewa ^b   Nej, Katarzyna ^b   Szymańska, Anna ^a   Szymańska, Jolanta ^a   Matyjasik, Joanna ^a   Cybulski, Cezary ^a   Jakubowska, Anna ^a   Górski, Bohdan ^a   Narod, Steven A ^c   more..

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF SZCZECIN   (Poland)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer susceptibility; Multiple organs; NOD2

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15;

ALLELE; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER; CANCER RISK; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; KIDNEY CANCER; LARYNX CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; STOMACH CANCER; THYROID CANCER;

EID: 22144498438     PISSN: 17312302     EISSN: None     Source Type: Journal    
DOI: 10.1186/1897-4287-3-2-59     Document Type: Article

References (30)

1. Cotran R, Kumar V and Robbins S (eds). Pathologic Basis of Disease. 5th edition.
2. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 1-5.
3. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G and Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606.
4. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S and Mathew CG. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 1925-8.
5. Gutierrez O, Pipaon C, Inohara N, Fontalba A, Ogura Y, Prosper F, Nunez G and Fernandez-Luna JL. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J Biol Chem 2002; 277: 41701-41705.
6. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S and Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276: 4812-4818.
7. Kurzawski G, Suchy J, Kladny J, Grabowska E, Mierzejewski M, Jakubowska A, Debniak T, Cybulski C, Kowalska E, Szych Z, Domagala W, Scott RJ and Lubinski J. The Nod2 3020insC mutation and the risk of colorectal cancer. Cancer Res 2004; 64: 1604-1606.
8. Polish Cancer Registry 2002.
9. Persson PG, Karlen P, Bernell O, Leijonmarck CE, Brostrom O, Ahlbom A and Hellers G. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994; 107: 1675-1679.
10. Nakajima H, Munukata A and Yoshida Y. Extra-intestinal cancers in Crohn's disease. Digestion 1990; 47: 1-7.
11. Bernstein C, Blanchard JF, Kliewer E and Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91: 854-862.
12. Patel M, Banerjee B, Block JG and Marshall JB. Gastric Crohn's disease complicated by adenocarcinoma of the stomach: case report and review of the literature. Am J Gastroenterol 1997; 92: 1368-1371.
13. Ikeuchi H, Kusonoki M, Yamamura T and Nishigami T. Crohn's disease associated with gastric cancer. J Gastroenterol 2002; 37: 47-49.
14. Estlein D, Ghana G, Weil R, Rath-Wolfson L and Wolloch Y. Early cancer in gastric Crohn's disease. Isr Med Assoc J 2001; 3: 379-380.
15. Fujimura Y, Kihara T, Uchida J, Hoshika K, Sato I, Eimoto T, Furukawa Y, Sone A and Ohashi K. Transitional cell carcinoma of the bladder associated with Crohn's disease: case report and review of the literature. Br J Radiol 1992; 65: 1040-1042.
16. Uriburu JC, Baig MK, Singh JJ, Weiss EG, Nogueras JJ and Wexner SE. An unusual way to diagnose a rare case of bladder carcinoma: a patient with Crohn's disease. Int J Colorectal Dis 2003; 18: 172-173.
17. Palli D, Trallori G, Saieva C, Tarantino O, Edili E, D'Albasio G, Pacini F and Masala G. General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence study. Gut 1998; 42: 175-179.
18. McLuggage WC and Allen DC. Ovarian granulomas: a report of 37 cases. J Clin Pathol 1997; 50: 324-327.
19. Weber AM, Ziegler C, Belinson JL, Mitchinson AR, Widrich T and Fazio V. Gynecologic history of women with inflammatory bowel disease. Obstet Gynecol 1995; 86: 843-847.
20. Nissen R, Lenz S, Stampe Sorensen S and Christensen KC. Ovarian cysts in women with inflammatory bowel disease. Acta Obstet Gynecol Scand 1988; 67: 237-240.
21. Bernstein D and Rogers A. Malignancy in Crohn's disease. Am J Gastroenterol 1996; 91: 434-440.
22. Van der Woude CJ, Kleibeuker JH, Jansen PL and Moshage H. Chronic inflammation, apoptosis and (pre-) malignant lesions in the gastrointestinal tract. Apoptosis 2004; 9: 123-130.
23. Wright JG and Christman JW. The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy. Am J Respir Med 2003; 2: 211-219.
24. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB and Bast RC Jr. A genetically defined model for human ovarian cancer. Cancer Res 2004; 1: 1655-1663.
25. Huang S, Robinson JB, Deguzman A, Bucana CD and Fidler IJ. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000; 60: 5334-9.
26. Gorski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzanska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, Narod SA and Lubinski J. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 2000; 66: 1963-1968.
27. Kurzawski G, Suchy J, Kladny J, Safranow K, Jakubowska A, Elsakov P, Kucinskas V, Gardovski J, Irmejs A, Sibul H, Huzarski T, Byrski T, Debniak T, Cybulski C, Gronwald J, Oszurek O, Clark J, Gozdz S, Niepsuj S, Slomski R, Plawski A, Lacka-Wojciechowska A, Rozmiarek A, Fiszer-Maliszewska L, Bebenek M, Sorokin D, Stawicka M, Godlewski D, Richter P, Brozek I, Wysocka B, Jawien A, Banaszkiewicz Z, Kowalczyk J, Czudowska D, Goretzki PE, Moeslein G and Lubinski J. Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland and the Baltic States. J Med Genet 2002; 39: E65.
28. Papaconstantinou I, Theodoropoulos G, Gazouli M, Panoussopoulos D, Mantzaris GJ, Felekouras E and Bramis J. Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population. Int J Cancer 2005; 114: 433-435.
29. Alhopuro P, Ahvenainen T, Mecklin JP, Juhola M, Jarvinen HJ, Karhu A and Aaltonen LA. NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. Cancer Res 2004; 64: 7245-7247.
30. Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, Newman B, Van Oene M, Cescon D, Greenberg G, Griffiths AM, St George-Hyslop PH and Siminovitch KA. Functional variants of the OCTN cation transporter genes are associated with Crohn's disease. Nat Genet 2004; 36: 471-475.